---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-065913"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:04:01.669572+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics reports positive Phase 2 results for paltusotine in carcinoid syndrome

## Summary
- Phase 2 trial: 63% reduction in mean flushing frequency (p<0.0001) for patients with >1/day at baseline.
- 60% reduction in mean excess bowel movements (p=0.02) for patients with >3/day at baseline; 61% reduction in flushing severity (p<0.0001).
- Paltusotine generally well-tolerated; no treatment-related severe or serious AEs; common AEs included diarrhea, abdominal pain, nausea, headache.
- Company plans to engage FDA to align on Phase 3 design; expects to initiate Phase 3 program by end of 2024.

## SEC filing metadata
- accession: 0001193125-24-065913
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312524065913/0001193125-24-065913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312524065913/d759755d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-065913
- JSON: https://secwatch.observer/filing/0001193125-24-065913.json
- Plain text: https://secwatch.observer/filing/0001193125-24-065913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.